Tiago Girao, serving as the Chief Financial Officer for Immunovant Inc. (NASDAQ: IMVT), reported the sale of 10,000 shares of the company's common stock on June 26, 2026. The transaction generated gross proceeds of approximately $384,600. The shares were liquidated at prices fluctuating between $38.00 and $38.90 per share, resulting in a weighted average execution price of $38.46.
This divestment activity was immediately preceded by Mr. Girao's acquisition of 10,000 shares through the exercise of stock options on the identical date. The acquisition was facilitated at an exercise price of $15.90 per share, representing a total capital outlay of $159,000. The options exercised originated from an award granted on May 1, 2025. The vesting schedule for these underlying shares was structured to release 25% on April 21, 2026, with the remaining balance vesting in 12 substantially equal quarterly installments over the subsequent three years, contingent upon Mr. Girao's continued employment with Immunovant.
Post-transaction, Mr. Girao's direct ownership stake in Immunovant common stock stands at 247,596 shares. The sale takes place while the stock trades at $38.77, a level near its 52-week high of $39.28. This valuation reflects a substantial 137% return over the past twelve months. According to InvestingPro analysis, the stock currently trades at a premium relative to its calculated Fair Value.
Market sentiment surrounding Immunovant has been influenced by recent clinical developments and analyst coverage. H.C. Wainwright upgraded its price target for IMVT to $40 from $35, maintaining a Buy rating. This adjustment was driven by promising data from the company's Phase 2 rheumatoid arthritis study. The trial data indicated significant response rates, with 72.7% of patients achieving ACR20 at week 16.
Similarly, BofA Securities raised its price target to $43 from $32. The firm cited a higher peak sales outlook for IMVT-1402, particularly regarding its potential in treating Graves' disease and challenging rheumatoid arthritis cases. Stifel also reiterated a Buy rating with a $49 price target following the company's fourth-quarter results and trial data, noting response rates above 70% in the study's open-label portion.
Broader corporate developments also impact investor perception. Roivant Sciences, which includes Immunovant in its portfolio, released its fourth-quarter earnings for fiscal year 2026. Although the parent company missed earnings per share expectations, it emphasized a strong cash position and strategic growth plans. These factors have contributed to increased investor optimism regarding Immunovant's clinical advancements.